[Cytochromes P450, drug disease and personified medicine. Part 2. Therapeutic drug monitoring as a method of monooxygenase activity assessment].
In part 2 of the review the authors consider factors, having influence on the state of monooxygenase system (MOS): cytochrome P-450 gene polymorphism, induction or inhibition of these systems under effect of drugs, crossed substance specificity of cytochrome P-450 forms. Various methodical approaches (genomic, proteomic, bioelectrical technologies, therapeutic drug monitoring) to receive full information about a profile of cytochrome P-450 for every specific person, are compared. Necessity of MOS individual features assessment for optimization of drug therapy is proved.
Archakov
A I
AI
Lisitsa
A V
AV
Petushkova
N A
NA
Karuzina
I I
II
D003577:Cytochrome P-450 Enzyme System / Q000502:physiology*; D016903:Drug Monitoring / Q000379:methods*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D018802:Patient-Centered Care / Q000592:standards*
D003577:Cytochrome P-450 Enzyme System